Hematopoietic stem cell transplantation for thalassemia.

Abstract

Hematopoietic stem cell transplantation (HSCT) represents the only cure for patients with thalassemia. At present HSCT in younger patients from an HLA- matched sibling donor offers 80% to 87% probability of cure according to risk classes. However, results HSCT in adult patients continue to be inferior due to advanced of disease. High-resolution tissue typing techniques have enabled transplant centres to offer allogeneic HSCT from unrelated donors to patients with thalassemia who could not benefit from matched sibling donor transplantation with results comparable to those obtained using sibling donors. Advances in transplantation biology have made it possible to perform haploidentical HSCT in patients with thalassemia who lack a related or unrelated matched donor. Although limited number of patients, results of unrelated cord blood transplantation for thalassemia are encouraging. Patients with graft failure could now benefit from second transplantation using the same donor with a high disease-free survival rate. Most ex-thalassemics continue to have disease and treatment-related complications acquired before transplantation which require adequate treatment following BMT.

• Authors: Javid Gaziev, Guido Lucarelli
• Journal: Current stem cell research & therapy (Curr Stem Cell Res Ther) Vol. 6 Issue 2 Pg. 162-9 (Jun 2011) ISSN: 2212-3946 [Electronic] United Arab Emirates
• PMID: 21190532 (Publication Type: Journal Article, Review)

Topics

• Adult
• Animals
• Hematopoietic Stem Cell Transplantation
• Humans
• Thalassemia (therapy)